Abstract 3581
Background
Ageing is a global phenomenon and has huge impact in healthcare. Still emerging in developing nations, there has been no major national innitiative focusing on oncologic geriatric patients (pts). The study describes a program to > 70y cancer pts in A C Camargo Cancer Center. We hypothesized that incorporating CGA into daily practice can improve individualized care.
Methods
Previous aims were to evaluate if: 1) CGA could be feasible in daily practice; 2) it could be useful as a tool in treatment/tx decision making; 3) analyse the impact of CGA in the selection of tx, with its ability to predict complications (such as dosis reduction, hospitalization, or tx discontinuation) in an Oncogeriatric Unit. The present study is to present the long term survival of those pts, candidates to receive systemic tx, who underwent CGA assessments, which included scales of: ADL (Katz, Lawton), mini-nutritional assessment, depression (GDS), comorbidities and polypharmacy. Patients were classified as fit, borderline or frail. Fit pts received mainly full treatment; frail/borderline pts, mainly modified tx or specific supportive care.
Results
From Oct 25/10-Dec/12/12, 638 pts were included to be prospectively evaluated - female 55%; cancers (%): breast 26, prostate 12, colorectal 12, hematologic 8. Katz A = 68%, Lawton 27=45%; polipharmacy ( > =5): 48%; depression 29%, undernutrition: 21%. We have previously presented (ASCO 2014) that there was an association between the choice of oncologic treatment (original vs modified or with additional dose reduction) with Katz, Lawton, depression and nutrition scales (p < =0.035); as well as the ability to complete the individualized proposed treatment, which was correlated with Lawton (p = 0.04) scale. Hospitalization during chemotherapy was associated with comorbidities, altered Katz, Lawton and depression scales (p < =0.038). With 610 pts evaluable, median survival was 51.7 months.
Conclusions
We could find a high long term survival of 70+ cancer pts, showing CGA to be feasible and allowing long term survival follow-up. However, many pts have been lost to follow-up. How to better perform in pts' adherence and to reduce bias must be a concern in real world geriatric oncology.
Clinical trial identification
Legal entity responsible for the study
Aldo L.A. Dettino; Grupo de Assistencia, Ensino e Pesquisa em Oncologia (GAEPO).
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4596 - Neoadjuvant Trial of nab-paclitaxel and Atezolizumab (Atezo), a PD-L1 inhibitor, in patients (pts) with chemo-insensitive Triple Negative Breast Cancer (TNBC)
Presenter: Jennifer Litton
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
5349 - Prognostic implications of circulating tumor cells (CTCs) after neoadjuvant chemotherapy for triple negative breast cancer (TNBC)
Presenter: Carolyn Hall
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2568 - A prediction model for pathological complete response after neoadjuvant chemotherapy of HER2-negative breast cancer patients
Presenter: Lothar Häberle
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
5413 - Evaluation of the MammaTyper® as a molecular predictor for pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) and outcome in patients with different breast cancer (BC) subtypes
Presenter: Peter A. Fasching
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2260 - Impact of clinical, morphologic and molecular characteristics on response to neoadjuvant systemic therapy (NAST) in metaplastic breast cancer (MpBC)
Presenter: Clinton Yam
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4722 - Evaluation of Human epidermal growth factor receptor 2 overexpression (HER2+) after administration of neoadjuvant treatment (NAT) and prognostic impact in breast cancer (BC)
Presenter: Duarte Machado
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4307 - Complete response (CR) to anthracycline-based chemotherapy using magnetic resonance imaging (MRI) predicts high rates of pathologic complete response (pCR) for triple negative breast cancer (TNBC) patients treated preoperatively with anthracycline and taxane-based regimens
Presenter: Maria Marin Alcala
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
5018 - Immunomonitoring of triple negative breast cancer patients undergoing neoadjuvant therapy (GBG89, Geparnuevo trial)
Presenter: Barbara Seliger
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3203 - Impact of breast cancer subtype on survival after lumpectomy versus mastectomy for early stage invasive breast cancer
Presenter: YU-CHEN Tsai
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4887 - Survival Outcomes of Dose Dense Neoadjuvant and Adjuvant Chemotherapy in Triple-Negative Breast Cancer Patients – Indian Scenario
Presenter: TANVI Sood
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract